Journal of Clinical Oncology, Vol 15, 277-284, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study [published erratum appears in J Clin Oncol 1997 Feb;15(2):866]

M al-Sarraf, K Martz, A Herskovic, L Leichman, JS Brindle, VK Vaitkevicius, J Cooper, R Byhardt, L Davis and B Emami
Providence Cancer Center, Southfield, MI 48075, USA.

PURPOSE: The present intergroup phase III randomized study compared combined chemotherapy (CT) plus radiotherapy (RT) treatment versus RT only in patients with locally advanced esophageal cancer. MATERIALS AND METHODS: Two courses of chemotherapy during 50 Gy RT followed by additional two courses of the same CT, versus 64 Gy RT alone were investigated. CT consisted of cisplatin 75 mg/m2 on day 1 [corrected] and fluorouracil (5FU) 1,000 mg/m2/d on days 1 to 4 every 4 weeks with RT and every 3 weeks post-RT. The main objective of the study was to compare overall survival between the two randomized treatment groups. Patients were stratified by tumor size, histology, and degree of weight loss. RESULTS: Sixty-two assessable patients were randomized to receive RT alone, and 61 to the combined arm. Patients characteristics were as follows: squamous cell cancer, 90% versus 85%; weight loss greater than 10 lb, 61% versus 69%; and tumor size, > or = 5 cm, 82% versus 80% on the RT and CT-RT arms, respectively. Systemic side effects, which consisted of nausea, vomiting, and renal and myelosuppression, occurred more frequently on the combined arm, while local side effects were similar in both groups. With a minimum follow-up time of 5 years for all patients, the median survival duration was 14.1 months and the 5- year survival rate was 27% in the combined treatment group, while the median survival duration was 9.3 months with no patients alive at 5 years in the RT-alone group (P < .0001). Additional patients (69) were treated with the same combined therapy and were analyzed. The results of the last group confirmed all of the results obtained with combined CT-RT in the randomized trial, with a median survival duration of 17.2 months and 3-year survival rate of 30%. CONCLUSION: We conclude that cisplatin and 5FU infusion given during and post-RT of 50 Gy is statistically superior to standard 64-Gy RT alone in patients with locally advanced esophageal cancer.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. P. M. Jansen, H. Boot, R. Dubbelman, M. Verheij, and A. Cats Postoperative chemoradiotherapy in gastric cancer--a phase I-II study of radiotherapy with dose escalation of weekly cisplatin and daily capecitabine chemotherapy Ann. Onc., March 1, 2010; 21(3): 530 - 534. [Abstract] [Full Text] [PDF]

				J. Zheng, G. Wang, G. Y. Yang, D. Wang, X. Luo, C. Chen, Z. Zhang, Q. Li, W. Xu, Z. Li, et al. Induction Chemotherapy with Nedaplatin with 5-FU Followed by Intensity-modulated Radiotherapy Concurrent with Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma Jpn. J. Clin. Oncol., January 19, 2010; (2010) hyp183v1. [Abstract] [Full Text] [PDF]

				S.-i. Kosugi, R. Sasamoto, T. Kanda, A. Matsuki, and K. Hatakeyama Retrospective Review of Surgery and Definitive Chemoradiotherapy in Patients with Squamous Cell Carcinoma of the Thoracic Esophagus Aged 75 Years or Older Jpn. J. Clin. Oncol., June 1, 2009; 39(6): 360 - 366. [Abstract] [Full Text] [PDF]

				G. KASUYA, K. OGAWA, H. SHIMOJI, W. TAMAKI, H. KARIMATA, T. TOITA, Y. KAKINOHANA, T. ARIGA, T. NISHIMAKI, and S. MURAYAMA Development of Gastro-lymphatic Fistula During Chemoradiotherapy for Advanced Esophageal Cancer: A Case Report Anticancer Res, February 1, 2009; 29(2): 525 - 527. [Abstract] [Full Text] [PDF]

				A. Adenis and T. Conroy Fluorouracil Should Continue to Be Incorporated in the Treatment of Localized Esophageal Cancer J. Clin. Oncol., January 20, 2009; 27(3): 467 - 468. [Full Text] [PDF]

				Y. Tachimori, N. Kanamori, N. Uemura, N. Hokamura, H. Igaki, and H. Kato Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma. J. Thorac. Cardiovasc. Surg., January 1, 2009; 137(1): 49 - 54. [Abstract] [Full Text] [PDF]

				E. C. Paulson, J. Ra, K. Armstrong, C. Wirtalla, F. Spitz, and R. R. Kelz Underuse of Esophagectomy as Treatment for Resectable Esophageal Cancer Arch Surg, December 1, 2008; 143(12): 1198 - 1203. [Abstract] [Full Text] [PDF]

				L. Bedenne and F. Bonnetain In Reply J. Clin. Oncol., September 1, 2007; 25(25): 4026 - 4027. [Full Text] [PDF]

				Y. Murakami, M. Kenjo, T. Uno, M. Oguchi, M. Shimada, T. Teshima, and the Japanese Patterns of Care Study Working Subgro Results of the 1999 2001 Japanese Patterns of Care Study for Patients Receiving Definitive Radiation Therapy without Surgery for Esophageal Cancer Jpn. J. Clin. Oncol., July 23, 2007; (2007) hym055v1. [Abstract] [Full Text] [PDF]

				L. Bedenne, P. Michel, O. Bouche, C. Milan, C. Mariette, T. Conroy, D. Pezet, B. Roullet, J.-F. Seitz, J.-P. Herr, et al. Chemoradiation Followed by Surgery Compared With Chemoradiation Alone in Squamous Cancer of the Esophagus: FFCD 9102 J. Clin. Oncol., April 1, 2007; 25(10): 1160 - 1168. [Abstract] [Full Text] [PDF]

				D. W. Gee and D. W. Rattner Management of Gastroesophageal Tumors Oncologist, February 1, 2007; 12(2): 175 - 185. [Abstract] [Full Text] [PDF]

				J. G. Izzo, U. Malhotra, T.-T. Wu, J. Ensor, R. Luthra, J. H. Lee, S. G. Swisher, Z. Liao, K.S. C. Chao, W. N. Hittelman, et al. Association of Activated Transcription Factor Nuclear Factor {kappa}B With Chemoradiation Resistance and Poor Outcome in Esophageal Carcinoma J. Clin. Oncol., February 10, 2006; 24(5): 748 - 754. [Abstract] [Full Text] [PDF]

				M Cominos, M A Mosleh-Shirazi, D Tait, A Henrys, and P Cornes Quantification and reduction of cardiac dose in radical radiotherapy for oesophageal cancer Br. J. Radiol., December 1, 2005; 78(936): 1069 - 1074. [Abstract] [Full Text] [PDF]

				G. de Manzoni, C. Pedrazzani, E. Laterza, F. Pasini, A. Grandinetti, M. Bernini, A. Ruzzenente, G. Zerman, A. Tomezzoli, and C. Cordiano Induction Chemoradiotherapy for Squamous Cell Carcinoma of the Thoracic Esophagus: Impact of Increased Dosage on Long-Term Results Ann. Thorac. Surg., October 1, 2005; 80(4): 1176 - 1183. [Abstract] [Full Text] [PDF]

				W. P. Tew, D. P. Kelsen, and D. H. Ilson Targeted Therapies for Esophageal Cancer Oncologist, September 1, 2005; 10(8): 590 - 601. [Abstract] [Full Text] [PDF]

				E. P.M. Jansen, H. Boot, M. Verheij, and C. J.H. van de Velde Optimal Locoregional Treatment in Gastric Cancer J. Clin. Oncol., July 10, 2005; 23(20): 4509 - 4517. [Abstract] [Full Text] [PDF]

				A. C. Berger, J. Farma, W. J. Scott, G. Freedman, L. Weiner, J. D. Cheng, H. Wang, and M. Goldberg Complete Response to Neoadjuvant Chemoradiotherapy in Esophageal Carcinoma Is Associated With Significantly Improved Survival J. Clin. Oncol., July 1, 2005; 23(19): 4330 - 4337. [Abstract] [Full Text] [PDF]

				F. Pasini, G. de Manzoni, C. Pedrazzani, A. Grandinetti, E. Durante, M. Gabbani, A. Tomezzoli, C. Griso, A. Guglielmi, G. Pelosi, et al. High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy Ann. Onc., July 1, 2005; 16(7): 1133 - 1139. [Abstract] [Full Text] [PDF]

				M. Tahara, A. Ohtsu, S. Hironaka, N. Boku, S. Ishikura, Y. Miyata, T. Ogino, and S. Yoshida Clinical Impact of Criteria for Complete Response (CR) of Primary Site to Treatment of Esophageal Cancer Jpn. J. Clin. Oncol., June 1, 2005; 35(6): 316 - 323. [Abstract] [Full Text] [PDF]

				M. Suntharalingam, J. Moughan, L. R. Coia, M. J. Krasna, L. Kachnic, D. G. Haller, C. G. Willet, M. J. John, B. D. Minsky, and J. B. Owen Outcome Results of the 1996-1999 Patterns of Care Survey of the National Practice for Patients Receiving Radiation Therapy for Carcinoma of the Esophagus J. Clin. Oncol., April 1, 2005; 23(10): 2325 - 2331. [Abstract] [Full Text] [PDF]

				K. Muro, T. Hamaguchi, A. Ohtsu, N. Boku, K. Chin, I. Hyodo, H. Fujita, W. Takiyama, and T. Ohtsu A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer Ann. Onc., June 1, 2004; 15(6): 955 - 959. [Abstract] [Full Text] [PDF]

				M. Koshy, N. Esiashvilli, J. C. Landry, C. R. Thomas Jr., and R. H. Matthews Multiple Management Modalities in Esophageal Cancer: Combined Modality Management Approaches Oncologist, April 1, 2004; 9(2): 147 - 159. [Abstract] [Full Text] [PDF]

				P. C. Enzinger and R. J. Mayer Esophageal Cancer N. Engl. J. Med., December 4, 2003; 349(23): 2241 - 2252. [Full Text] [PDF]

				J. S. Donington, D. L. Miller, M. S. Allen, C. Deschamps, F. C. Nichols III, and P. C. Pairolero Tumor response to induction chemoradiation: influence on survival after esophagectomy Eur. J. Cardiothorac. Surg., October 1, 2003; 24(4): 631 - 637. [Abstract] [Full Text] [PDF]

				S. Koyama and H. Tsujii Proton Beam Therapy with High-Dose Irradiation for Superficial and Advanced Esophageal Carcinomas Clin. Cancer Res., September 1, 2003; 9(10): 3571 - 3577. [Abstract] [Full Text] [PDF]

				S. Ishikura, K. Nihei, A. Ohtsu, N. Boku, S. Hironaka, K. Mera, M. Muto, T. Ogino, and S. Yoshida Long-Term Toxicity After Definitive Chemoradiotherapy for Squamous Cell Carcinoma of the Thoracic Esophagus J. Clin. Oncol., July 15, 2003; 21(14): 2697 - 2702. [Abstract] [Full Text] [PDF]

				Y. Nishimura, R. Koike, K. Nakamatsu, S. Kanamori, M. Suzuki, H. Shigeoka, and H. Shiozaki Concurrent Chemoradiotherapy with Protracted Infusion of 5-FU and Cisplatin for Postoperative Recurrent or Residual Esophageal Cancer Jpn. J. Clin. Oncol., July 1, 2003; 33(7): 341 - 345. [Abstract] [Full Text] [PDF]

				R Jacob, N D Hawkes, N Dallimore, E G Butchart, G A O Thomas, and T S Maughan Squamous carcinoma in an oesophageal foregut cyst Br. J. Radiol., May 1, 2003; 76(905): 343 - 346. [Abstract] [Full Text] [PDF]

				J. S. Waters, D. Tait, D. Cunningham, A. R. Padhani, M. E. Hill, S. Falk, F. Lofts, A. Norman, J. Oates, and A. Hill A multicentre phase II trial of primary chemotherapy with cisplatin and protracted venous infusion 5-fluorouracil followed by chemoradiation in patients with carcinoma of the oesophagus Ann. Onc., November 1, 2002; 13(11): 1763 - 1770. [Abstract] [Full Text] [PDF]

				K. Shigemitsu, Y. Naomoto, Y. Shirakawa, M. Haisa, M. Gunduz, and N. Tanaka A Case of Advanced Esophageal Cancer with Extensive Lymph Node Metastases Successfully Treated with Multimodal Therapy Jpn. J. Clin. Oncol., August 1, 2002; 32(8): 310 - 314. [Abstract] [Full Text] [PDF]

				M. S. Bains, A. Stojadinovic, B. Minsky, V. Rusch, A. Turnbull, R. Korst, R. Ginsberg, D. P. Kelsen, and D. H. Ilson A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: Initial results J. Thorac. Cardiovasc. Surg., August 1, 2002; 124(2): 270 - 277. [Abstract] [Full Text] [PDF]

				L. R. Prosnitz Reducing Treatment-Related Morbidity and Mortality in Early-Stage Hodgkin's Disease and Why the Recent Southwest Oncology Group Trial Is Not the Way to Go J. Clin. Oncol., May 1, 2002; 20(9): 2225 - 2228. [Full Text] [PDF]

				T. Conroy, P.-L. Etienne, A. Adenis, M. Ducreux, B. Paillot, J. Oliveira, J.-F. Seitz, E. Francois, E. Van Cutsem, D. J. T. Wagener, et al. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival Ann. Onc., May 1, 2002; 13(5): 721 - 729. [Abstract] [Full Text] [PDF]

				C. G. Willett Radiation Dose Escalation in Combined-Modality Therapy for Esophageal Cancer J. Clin. Oncol., March 1, 2002; 20(5): 1151 - 1153. [Full Text] [PDF]

				J. W.C. Entwistle III and M. Goldberg Multimodality therapy for resectable cancer of the thoracic esophagus Ann. Thorac. Surg., March 1, 2002; 73(3): 1009 - 1015. [Abstract] [Full Text] [PDF]

				M. Morihiro, N. Boku, A. Ohtsu, S.'i. Miyamoto, and S. Ishikura Advanced Esophageal Cancer with Esophago-bronchial Fistula Successfully Treated by Chemoradiation Therapy with Additional Endoscopic Resection: a Case Report Jpn. J. Clin. Oncol., February 1, 2002; 32(2): 59 - 63. [Abstract] [Full Text] [PDF]

				S. Hironaka, T. Hasebe, T. Kamijo, A. Ohtsu, N. Boku, S. Yoshida, H. Saitoh, and A. Ochiai Biopsy Specimen Microvessel Density Is a Useful Prognostic Marker in Patients with T2-4M0 Esophageal Cancer Treated with Chemoradiotherapy Clin. Cancer Res., January 1, 2002; 8(1): 124 - 130. [Abstract] [Full Text] [PDF]

				J. I. Lew, W. E. Gooding, U. Ribeiro Jr, A. V. Safatle-Ribeiro, and M. C. Posner Long-term Survival Following Induction Chemoradiotherapy and Esophagectomy for Esophageal Carcinoma Arch Surg, July 1, 2001; 136(7): 737 - 742. [Abstract] [Full Text] [PDF]

				M. Muto, A. Ohtsu, Y. Miyata, Y. Shioyama, N. Boku, and S. Yoshida Self-expandable Metallic Stents for Patients with Recurrent Esophageal Carcinoma After Failure of Primary Chemoradiotherapy Jpn. J. Clin. Oncol., June 1, 2001; 31(6): 270 - 274. [Abstract] [Full Text] [PDF]

				S P L Dexter, H Sue-Ling, M J McMahon, P Quirke, N Mapstone, and I G Martin Circumferential resection margin involvement: an independent predictor of survival following surgery for oesophageal cancer Gut, May 1, 2001; 48(5): 667 - 670. [Abstract] [Full Text] [PDF]

				H. Sumi, A. Ohtsu, N. Boku, M. Muto, F. Nagashima, K. Hosokawa, S. Yoshida, M. Satake, S. Ishikura, and T. Ogino A Case of Inoperable Esophageal Carcinoma with Hepatic and Nodal Metastases Which Showed a Long-term Survival after Chemoradiotherapy Including Nedaplatin Jpn. J. Clin. Oncol., September 1, 2000; 30(9): 406 - 409. [Abstract] [Full Text] [PDF]

				P. R. Miller, S. L. Jackson, B. C. Pineau, and E. A. Levine Radiation-induced gastrointestinal stromal sarcoma of the esophagus Ann. Thorac. Surg., August 1, 2000; 70(2): 660 - 662. [Abstract] [Full Text] [PDF]

				L. R. Coia, B. D. Minsky, B. A. Berkey, M. J. John, D. Haller, J. Landry, T. M. Pisansky, C. G. Willett, J. P. Hoffman, J. B. Owen, et al. Outcome of Patients Receiving Radiation for Cancer of the Esophagus: Results of the 1992-1994 Patterns of Care Study J. Clin. Oncol., February 1, 2000; 18(3): 455 - 455. [Abstract] [Full Text] [PDF]

				M. J. Krasna, Y. S. Mao, J. R. Sonett, G. Tamura, R. Jones, M. Suntharalingam, and S. J. Meltzer P53 gene protein overexpression predicts results of trimodality therapy in esophageal cancer patients Ann. Thorac. Surg., December 1, 1999; 68(6): 2021 - 2024. [Abstract] [Full Text] [PDF]

				M. A. Chidel, T. W. Rice, D. J. Adelstein, P. A. Kupelian, J. H. Suh, and M. Becker Resectable Esophageal Carcinoma: Local Control with Neoadjuvant Chemotherapy and Radiation Therapy Radiology, October 1, 1999; 213(1): 67 - 72. [Abstract] [Full Text]

				A. Ohtsu, N. Boku, K. Muro, K. Chin, M. Muto, S. Yoshida, M. Satake, S. Ishikura, T. Ogino, Y. Miyata, et al. Definitive Chemoradiotherapy for T4 and/or M1 Lymph Node Squamous Cell Carcinoma of the Esophagus J. Clin. Oncol., September 1, 1999; 17(9): 2915 - 2915. [Abstract] [Full Text] [PDF]

				J. S. Cooper, M. D. Guo, A. Herskovic, J. S. Macdonald, J. A. Martenson Jr, M. Al-Sarraf, R. Byhardt, A. H. Russell, J. J. Beitler, S. Spencer, et al. Chemoradiotherapy of Locally Advanced Esophageal Cancer: Long-term Follow-up of a Prospective Randomized Trial (RTOG 85-01) JAMA, May 5, 1999; 281(17): 1623 - 1627. [Abstract] [Full Text] [PDF]

				D. P. Kelsen, R. Ginsberg, T. F. Pajak, D. G. Sheahan, L. Gunderson, J. Mortimer, N. Estes, D. G. Haller, J. Ajani, W. Kocha, et al. Chemotherapy Followed by Surgery Compared with Surgery Alone for Localized Esophageal Cancer N. Engl. J. Med., December 31, 1998; 339(27): 1979 - 1984. [Abstract] [Full Text] [PDF]

				W. Z. Tamim, R. S. Davidson, R. M. Quinlan, M. A. O'Shea, R. K. Orr, and R. S. Swanson Neoadjuvant Chemoradiotherapy for Esophageal Cancer: Is It Worthwhile? Arch Surg, July 1, 1998; 133(7): 722 - 726. [Abstract] [Full Text] [PDF]